JNJ 68179280
Alternative Names: JNJ-68179280; JNJ-9280Latest Information Update: 28 Jun 2024
Price :
$50 *
At a glance
- Originator Janssen Research & Development
- Class Anti-inflammatories
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Inflammatory bowel diseases
Most Recent Events
- 28 Jun 2024 No recent reports of development identified for phase-I development in Inflammatory-bowel-diseases(In volunteers) in USA (PO, Capsule)
- 14 Apr 2021 Preclinical trials in Unspecified in USA (PO) before April 2021
- 14 Apr 2021 Janssen Research & Development plans phase I trial (In volunteers) in USA (PO, Capsule) in April 2021 (NCT04844463)